



UNIVERSITI PUTRA MALAYSIA

CHARACTERIZATION OF BACTERIOPHAGES FOR *E. coli* CAUSING COLIBACILOSIS IN CHICKEN

NUR ATHIRAH NUR AZAMI

FBSB 2015 122

PENGESAHAN

Dengan ini adalah disahkan bahawa projek yang bertajuk “Characterization of Bacteriophages for *Escherichia coli* Causing Colibacilosis in Chicken” telah disiapkan serta dikemukakan kepada Jabatan Mikrobiologi oleh NUR ATHIRAH BINTI NOOR AZAMI (161050) sebagai syarat untuk kursus BMY 4999 Projek.

Disahkan oleh:

Prof. Madya Dr. Sieo Chin Chin

Penyelia

Jabatan Mikrobiologi

Fakulti Bioteknologi dan Sains Biomolekul

Universiti Putra Malaysia

Tarikh:

Prof. Madya Dr. Muhajir Hamid

Ketua

Jabatan Mikrobiologi

Fakulti Bioteknologi dan Sains Biomolekul

Universiti Putra Malaysia

Tarikh:

ABSTRACT

The emergence of pathogenic bacteria resistant towards most of the antimicrobial agents has risen up the bacteriophage therapy research through out the world. Rather than using antibiotics, it is suggested that the bacterial infection is treated by the administration of bacteriophages. The research was performed in order to characterise the bacteriophages against the pathogenic bacteria *Escherichia coli* (*E. coli*) that have been identified as the causing agent of the colibacilosis in chicken. The host bacteria of the bacteriophages were *E. coli* strains 712X, 141 1E, 141 2E, and 141 3E. All of these *E. coli* strains were serotype O1:K1 which is causative agent for colibacilosis in chicken. There are two bacteriophages that are been characterised which are ØMS1 and ØMS2. All the bacteriophages were characterised using physiological characterisation. Both bacteriophages show their lytic ability toward *E. coli* strains 7I2X only. It is shown that ØMS1 is better in comparison of ØMS2. Both ØMS1 and ØMS2 demonstrated an optimum multiplicity of infection (MOI) of 0.01 and 0.1 respectively. Based on adsorption rate, ØMS1 reach its maximum value (99.8%) at 8 minutes while ØMS2 reach its maximum value (99.6%) at 10 minutes. In the single step growth curve of the bacteriophages, ØMS1 have longer latent period (25 min) compare to ØMS2 (15 min), with higher burst size of 200 bacteriophage particles per infected cell and 175 bacteriophage particles per infected cell respectively. Both ØMS1 and ØMS2 are stable in temperature range of 37-40 °C with pH range of 6-9.

ABSTRAK

Kemunculan bakteria patogenik yang tahan terhadap kebanyakan ejen antimikrob telah meningkatkan penyelidikan terapi bacteriofaj di seluruh dunia. Daripada menggunakan antibiotik, adalah dicadangkan bahawa jangkitan bakteria dirawat dengan penggunaan bacteriofaj. Kajian ini dilakukan untuk mencirikan bacteriofaj terhadap bakteria patogenik *Escherichia coli* (*E. coli*) yang telah dikenal pasti sebagai agen yang menyebabkan colibacilosis kepada ayam. Organisma ujian untuk bacteriofaj dikenalpasti sebagai bakteria *E. coli* strain 712X, 141 1E, 2E 141, dan 141 3E. Semua strain *E. coli* ini adalah serotype O1: K1 yang merupakan agen penyebab untuk colibacilosis dalam ayam. Terdapat dua bacteriofaj yang telah dicirikan iaitu ØMS1 dan ØMS2. Semua bacteriofaj telah dicirikan menggunakan pencirian fisiologi. Kedua-dua bacteriofaj menunjukkan keupayaan ‘lytic’ mereka terhadap *E. coli* strain 712X sahaja. MOI optimum untuk kedua-dua ØMS1 dan ØMS2 adalah 0.01 dan 0.1 masing-masing. Daripada kajian, ia menunjukkan bahawa ØMS1 adalah lebih baik berbanding daripada ØMS2. Berdasarkan kadar penjerapan, nilai maksimum (99.8%) ØMS1 pada 8 minit walhal nilai maksimum (99.6%) ØMS2 pada 10 minit. Graf ‘single-step growth’ menunjukkan bahawa ØMS1 mempunyai tempoh ‘latent’ yang lebih lama (25 min) berbanding ØMS2 (15 min), dengan saiz ‘burst’ lebih tinggi 200 zarah bakteriofaj setiap sel yang dijangkiti dan 175 zarah bakteriofaj setiap sel dijangkiti masing-masing. Kedua-dua ØMS1 dan ØMS2 stabil dalam suhu 37-40 °C dengan pH 6-9.

ACKNOWLEDGEMENT

First and foremost, I would like to extend my greatest appreciation to my project supervisor, Assoc. Prof. Dr. Sieo Chin Chin for her dedication, guidance, valuable advised and moral support during the whole duration of my research project.

Besides, I would like to thank my senior Mohd Shaufi for sharing the knowledge, giving me patience and kind guidance. I would to thanks others mentor that involve voluntary or involuntary in the progress of my project. I am also very thankful to the member of Microbiology Laboratory in Institute of Biosciences for the generous assistance while I am working in the lab.

In addition, my heartiest gratitude goes to Nor Zawani, Zatul Najihah, and Chan Weng Yee. I am so grateful to have all of you as my lab mates. Thanks for the support, everythings valuable information and excellent teamwork to me all the times.

Last but not least, I wish to my beloved parent; Mr Noor Azami bin Saidun and Mrs Rashimawati binti Hashim, family member and lovely friends for their immeasurable love, understanding, sacrifices, patience and encouragement through my study.

TABLE OF CONTENTS

PENGESAHAN	i
ABSTRACT	ii
ABSTRAK	iii
ACKNOWLEDGEMENT	iv
LIST OF ABBREVIATION	vii
LIST OF TABLES	viii
LIST OF FIGURES	ix
CHAPTER 1	1
INTRODUCTION	1
CHAPTER 2	3
LITERATURE REVIEW	3
2.1 Escherichia coli (E. coli)	3
2.1.1 Role of <i>E. coli</i> in Poultry Industry	4
2.1.2 APEC in Colibacillosis	5
2.2 The Antibiotics in Livestocks Production	7
2.3 Bacteriophages	9
2.3.1 Introduction	9
2.4 Bacteriophage Therapy	10
CHAPTER 3	14
MATERIALS AND METHODS	14
3.1 Media Preparation	14
3.2 Chemical Preparation	14
3.3 Bacteria Preparation	14
3.3.1 Growth and Maintenance of Bacteria	14
3.3.2 Bacteria Growth Curve	14
3.3.3 Bacteria Concentration	15
3.4 Physiological Characterisation of Bacteriophage	15
3.4.1 Growth and Maintenance of Bacteriophages	15
3.4.2 Determination of Bacteriophage Titre	15
3.4.3 Host Range Test	16
3.4.4 Multiplicity of Infection (MOI)	16
3.4.5 Adsorption rate of Bacteriophage	17
3.4.6 Single-Step Growth Curve	17
3.4.7 Determination of Optimum pH	18
3.4.8 Determination of Optimum Temperature	18
CHAPTER 4	19
RESULTS AND DISCUSSION	19
4.1 Growth Curve of Bacteria	19
4.2 Physiological Characterisation of Bacteriophage	20
4.2.1 Host Range Determination	20
4.2.2 Multiplicity of Infection (MOI)	21
4.2.3 Single-Step Growth Curve	25

4.2.4	Adsorption Rate of Bacteriophage	27
4.2.5	Determination of Optimum pH	28
4.2.6	Determination of Optimum Temperature	32
CHAPTER 5		36
CONCLUSION AND RECOMMENDATIONS		36
REFERENCES		37
APPENDICES		42



LIST OF ABBREVIATION

Abbreviation

ml	mililiter
μ l	microliter
g	Gram
%	Percent
$^{\circ}$ C	Degree Celsius
h	Hour
OD	Optical density
min	Minute

LIST OF TABLES

Table	Caption	Page
1	Growth curve of <i>E. coli</i> strains 7I2X over time	29

LIST OF FIGURES

Figures	Caption	Page
1	Chicken with symptoms of Colibacillosis.	5
2	Fibrin deposited in chicken carcass	6
3	Growth curve of <i>E. coli</i> strains 7I2X over time	20
4	Bacteriophage titre of ØMS1 and bacteria (<i>E. coli</i> strain 7I2X) concentration over time for different MOIs (0.01, 0.1 and 1)	23
5	Bacteriophage titre of ØMS2 and bacteria (<i>E. coli</i> strain 7I2X) concentration over time for different MOIs (0.01, 0.1 and 1)	25
6	Single-step growth curve of ØMS1 and ØMS2	27
7	The adsorption rate (%) of ØMS1 and ØMS2 over time.	28
8	The lytic ability of ØMS1 and ØMS2 over time at OD _{600nm}	29
9	Determination of optimum pH for lytic activity of ØMS1	30
10	Determination of optimum pH for lytic activity of ØMS2	32
11	Determination of optimum temperature for lytic activity of ØMS1:	34
12	Determination of optimum temperature for lytic activity of ØMS2:	36

CHAPTER 1

INTRODUCTION

Avian pathogenic *Escherichia coli* (APEC) caused a huge economic damage to the poultry industry due to high mortality, slower growth, a lower feed conversion efficiency and condemnation of carcasses at the abattoir. Inhalation of dust contaminated with high concentrations of *E. coli* can infect the air sacs and lungs, bacteria can enter the bloodstream, causing systemic disease known as colibacillosis.

Colibacillosis is a disease of severe economic significance to all poultry producers worldwide and is characterized by a diverse array of lesions. Recent reports in Western Europe implicate a resurgence of this disease in the poultry industry, particularly in chicken layers (Zanella et al., 2000; Vandekerchove et al., 2004; Jordan et al., 2005). Depending on the virulence status of the strain, host status and presence and type of predisposing factors, the infection manifests as an initial septicaemia that is followed by either sudden death or localized inflammation in multiple organs. The disease is traditionally treated with antibiotics, but due to frequent use of antibiotics many APEC strains have become multidrug resistant.

Normally, disinfectants are used in poultry houses to prevent colibacillosis and other diseases carry-over between sequential flocks, to lower the number of specific pathogens as much as possible. Furthermore, it was determined if these APEC isolates were resistant against the most included active ingredients in routinely used disinfectants in the poultry industry. High resistance percentages were found against antibiotics frequently used in the poultry industry such as ampicillin,

nalidixic acid, sulfonamides and trimethoprim. The use of antibiotics raises a public health concern, due to transfer of resistance genes or resistant bacteria from animals to humans. Therefore the use of bacteriophage therapy was tested as alternative treatment for colibacillosis in chickens.

Bacteriophages are viruses that infect and kill bacteria. Bacteriophages kill bacteria, which provide an opportunity to use bacteriophage as an alternative to antibiotics to prevent and treat bacterial infections and to reduce foodborne pathogens on agricultural products.

The general objective of this study is to characterise bacteriophages for the *E. coli* causing colibacillosis in chicken. The specific objectives are as follows:

1. To study the growth kinetics of the *E. coli* causing colibacillosis in chickens.
2. To characterise the bacteriophage isolated against *E. coli* causing colibacillosis in chickens.

REFERENCES

- AAM. *The role of antibiotics in Agriculture*. 2002;1-15.
- Abedon ST, Lysis from without. *Bacteriophage* 1:1–4 (2011).
- Ashelford KE, Day MJ, Fry JC. Elevated abundance of bacteriophage infecting bacteria in soil. *Appl. Environ. Microbiol.* 2003;69:(1)285-289.
- Ashelford KE, Norris SJ, Fry JC, Bailey MJ, Day MJ. Seasonal population dynamics and interactions of competing bacteriophages and their host in the Rhizosphere. *Appl. Environ. Microbiol.* 2000;66(10):4193-4199.
- Atterbury RJ, Connerton PL, Dodd CER, Rees CED, Connerton IF. Application of host-specific bacteriophages to the surface of chicken skin leads to a reduction in recovery of *Campylobacter jejuni*. *Appl. Environ. Microbiol.* 2003;69(10):6302-6306.
- Bains BS. *A manual of poultry diseases*: Roche Publishing; 1979.
- Barnes HJ, Gross WB. Colibacillosis. In: Calnek BW, Barnes HJ, Beard CW, McDougald LR, Saif YM, eds. *Diseases of Poultry*. 10th ed. Ames, IA: IowaState University Press; 1997:131-141.
- Barrow P, Lovell M, Berchieri A, Jr. Use of Lytic Bacteriophage for control of experimental *Escherichia coli* septicemia and meningitis in chickens and calves. *Clin. Diagn. Lab. Immunol.* 1998;5(3):294-298.
- Bogovazova GG, Voroshilova NN, Bondarenko VM, Gorbatkova GA, Afanas'eva EV, Kazakova TB, Smirnov VD, Mamleeva AG, Glukharev YI, Erastova EI, Krylov IA, Ovcherenko TM, Baturo AP, Yatsyk GV, Aref'eva NA. Immunobiological properties and therapeutic effectiveness of preparations from *Klebsiella* bacteriophages. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 1992;3:30-33.
- Bogovazova GG, Voroshilova NN, Bondarenko VM. The efficacy of *Klebsiella pneumoniae* bacteriophage in the therapy of experimental *Klebsiella* infection. *Zh. Mikrobiol. Epidemiol. Immunobiol.* 1991;4:5-8.
- Boratyński J, Syper D, Weber-Dabrowska B, Łusiak-Szelachowska M, Poźniak G, Górska A. Preparation of endotoxin-free bacteriophages. *Cell. Mol. Biol. Lett.* 2004;9(2):253-259.
- Brüssow H, Canchaya C, Hardt W. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion. *Microbiol. Mol. Biol. Rev.* 2004;68(3):560-602.
- Caroff M, Karibian D. Structure of bacterial lipopolysaccharides. *Carbohydrate Res.* 2003;338(23):2431-2447.
- Caso JL, Reyes-Gavilan CGDL, Herrero M, Montilla A, Rodriguez A and Suarez JE, Isolation and characterization of temperate and virulentbacteriophages of *Lactobacillus plantarum*. *J Dairy Sci* 78:741–750(1995).
- Cerveny KE, DePaola A, Duckworth DH, Gulig PA. Phage therapy of local and systemic disease caused by *Vibrio vulnificus* in iron-dextran-treated mice. *Infect. Immun.* 2002;70(11):6251-6262.
- Chibani-Chennoufi S, Sidoti J, Bruttin A, Kutter E, Sarker S, Brussow H. *In vitro* and *in vivo* bacteriolytic activities of *Escherichia coli* phages: implications for phage therapy. *Antimicrob. Agents Chemother.* 2004;48(7):2558-2569.
- Cruickshank R, Duguid, JP, Marmion, BP, Swain, RHA. *Escherichia, Klebsiella, Proteus* and other *Enterobacteria*. *Medical Microbiology; a guide to the*

- laboratory diagnosis and control of infection.* Vol 2. 12th ed. Edinburgh: Churchill Livingstone; 1975:428-439.
- Culbertson Jr. R, Osburn BI. The biologic effects of bacterial endotoxin: A short review. *Vet. Res. Comm.* 1980;4(1):3-14.
- Delicato ER, de Brito BG, Gaziri LCJ, Vidotto MC. Virulence-associated genes in *Escherichia coli* isolates from poultry with colibacillosis. *Vet Microbiol.* 2003;94(2):97-103.
- Dho-Moulin M, Fairbrother JM. Avian pathogenic *Escherichia coli* (APEC). *Vet. Res.* 1999;30(2-3):299-316.
- Dziva F, Stevens MP. Colibacillosis in poultry: unravelling the molecular basis of virulence of avian pathogenic *Escherichia coli* in their natural hosts. *Avian Pathol.* 2008;37(4):355-356.
- EMEA. *Draft report of the CVMP's ad hoc working party on antimicrobial resistance (ARWP). Development of resistance in the European union. Including risk assessment on the possibility of a transfer of resistance from animal to man.* 1999.
- FDA. *Effect of the use of antimicrobials in food-producing animals on pathogen load: systematic review of the published literature.* Alexandria, VA: Exponent 2000.
- FDA. Food additives permitted for direct addition to food for human consumption; Bacteriophage preparation. *Federal Register: Rules and Regulations.* 2006;71(160).
- FDA. Human-Use Antibiotics in Livestock Production. 2000.
- Fiorentin L, Vieira ND, Barioni Jr W, Barros S. "In vitro" characterization and "In vivo" properties of *Salmonella* lytic bacteriophages isolated from free-range chickens. *Poult. Sci.* 2004;6(2):105-112.
- García E, López, R. Los bacteriófagos y sus productos génicos como agentes antimicrobianos. *Revista Espanola de Quimioterapia.* 2002;15(4):306-312.
- García V. Colibacillosis en las granjas avícolas. *E. coli* una oportunista siempre presente. Paper presented at: XXXVII Symposium WPSA, 2000; Barcelona, Spain.
- García V. Colibacillosis en las granjas avícolas. *E. coli* una oportunista siempre presente, p. 118-122. Paper presented at: XXXVII Symposium WPSA, 2000; Barcelona, Spain.
- Goodridge L, Abedon ST. Bacteriophage biocontrol and bioprocessing: Application of phage therapy to industry. *SIM News.* 2003;53(6):254-262.
- Górski A, Nowaczyk M, Weber-Dabrowska B, Kniotek M, Boratynski J, Ahmed A, Dabrowska K, Wierzbicki P, Switala-Jelen K, Opolski A. New insights into the possible role of bacteriophages in transplantation. *Transplantation proceedings.* 2003;35(6):2372-2373.
- Grabow WOK. Bacteriophages : Update on application as models for viruses in water. *Water S. A.* . 2001;27(2):251-268.
- Gross W. Colibacillosis. In: *Diseases of Poultry.* 9th ed: Iowa State University Press; 1991:138-144.
- Hammoudi A, Aggad H. Antibioresistance of *E. coli* strains isolated from chicken colibacillosis in Western Algeria. *Turk. J. Vet. Anim. Sci.* 2008;32 (2):123-126.
- Huff WE, Huff GR, Rath NC and Donoghue AM, Evaluation of the influence of bacteriophage titer on the treatment of colibacillosis in broiler chickens. *Poultry Sci* 85:1373–1377 (2006).

- Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Alternatives to antibiotics: utilization of bacteriophage to treat colibacillosis and prevent foodborne pathogens. *Poult.Sci.* 2005;84(4):655-659.
- Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Bacteriophage treatment of a severe *Escherichia coli* respiratory infection in broiler chickens. *Avian Dis.* 2003;47(4):1399-1405.
- Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Evaluation of aerosolspray and intramuscular injection of bacteriophage to treat an *Escherichia coli* respiratory infection. *Poult.Sci.* 2003;82(7):1108-1112.
- Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Prevention of *Escherichia coli* infection in broiler chickens with a bacteriophage aerosol spray. *Poult.Sci.* 2002;81(10):1486-1491.
- Huff WE, Huff GR, Rath NC, Balog JM, Donoghue AM. Therapeutic efficacy of bacteriophage and Baytril (enrofloxacin) individually and in combination to treat colibacillosis in broilers. *Poult.Sci.* 2004;83(12):1944-1947.
- Huff WE, Huff GR, Rath NC, Balog JM, Xie H, Moore PA, Jr., Donoghue AM. Prevention of *Escherichia coli* respiratory infection in broiler chickens with bacteriophage (SPR02). *Poult.Sci.* 2002;81(4):437-441.
- Huff WE, Huff GR, Rath NC, Donoghue AM. Evaluation of the influence of bacteriophage titer on the treatment of colibacillosis in broiler chickens. *Poult.Sci.* 2006;85(8):1373-1377.
- Kaiser G. The prokaryotic cell: bacteria. *Microbiology Lecture Guide*; 2004.
- Knöbl T, Gomes TAT, Vieira MAM, Ferreira F, Bottino JA, Ferreira AJP. Some adhesins of avian pathogenic *Escherichia coli* (APEC) isolated from septicemic poultry in Brazil. *Braz. J. Microbiol.* 2006;37(3):379-384.
- Kucharewicz-Krukowska A, Slopek S. Immunogenic effect of bacteriophage in patients subjected to phage therapy. *Arch. Immunol. Ther. Exp.* 1987;35(5):553- 561.
- Kudva IT, Jelacic S, Tarr PI, Youderian P and Hodve CJ, Biocontrol of *Escherichia coli* O157 with O157-specific bacteriophages. *Appl EnvironMicrobiol* 65:3767-3773 (1999).
- Leverentz B, Conway WS, Camp MJ, Janisiewicz WJ and Abuladze T, Biocontrol of *Listeria monocytogenes* on fresh-cut produce by treatment with lytic bacteriophages and a bacteriocin. *Appl Environ Microbiol* 69:4519-4526 (2003).
- Levy SB. Factors impacting on the problem of antibiotic resistance. *J.Antimicrob. Chemother.* 2002;49(1):25-30.
- Loessner MJ. Improved procedure for bacteriophage typing of *Listeria* strains and evaluation of new phages. *Appl. Environ. Microbiol.* 1991;57(3):882-884.
- López R. Bacteriófagos: de la Biología Molecular a su uso terapéutico. <http://www.racve.es/actividades/medicina-veterinaria/2004-11-03RubenLopez.htm>. Real academia de Ciencias Veterinarias; 2004:1-17.
- Lu Z, Breidt Jr F, Fleming HP, Altermann E and Klaenhammer TR, Isolation and characterization of a *Lactobacillus plantarum*bacteriophage, JL-1, from a cucumber fermentation. *Int J FoodMicrobiol* 84:225-235 (2003).
- Medappa N. Cholera bacteriophages revisited. *ICMR Bulletin.* 2002;32(4):33-37.
- Mellata M, Dho-Moulin M, Dozois CM, Curtiss III R, Brown PK, Arne P, Bree A, Desautels C, Fairbrother JM. Role of virulence factors in resistance of AvianPathogenic *Escherichia coli* to serum and in pathogenicity. *Infect. Immun.* 2003;71(1):536-540.

- Mudgal P, Breidt Jr F, Lubkin SR and Sandeep KP. Quantifying the significance of phage attack on starter cultures: a mechanistic model for population dynamics of phages and their hosts isolated from fermenting sauerkraut. *Appl Environ Microbiol* 72:3908–3915 (2006).
- Muller-Merbach M, Kohler K and Hinrichs J, Environmental factors for phage-induced fermentation problems: replication and adsorption of the *Lactococcus lactis* phage P008 as induced by temperature and pH. *Food Microbiol* 24:695–702 (2007).
- NCBI. Phages taxonomy/ List. *Genome*: NCBI database; 2009:<http://www.ncbi.nlm.nih.gov/genomes/genlist.cgi?taxid=10239&type=10236&name=Phages>.
- Nelson D. Phage Taxonomy: We agree to disagree. *J. Bacteriol.* 2004;186(21):7029-7031.
- Pasharawipes T, Manopvisetcharan J and Flegel TW, Phage treatment of *Vibrio harveyi*: a general concept of protection against bacterial infection. *Res J Microbiol* 6:560–567 (2011).
- Pourbakhsh SA, Boulian M, Martineau-Doizé B, Dozois CM, Desautels C, Fairbrother JM. Dynamics of *Escherichia coli* infection in experimentally inoculated chickens. *Avian Dis.* 1997;41(1):221-233.
- Prins JM, Van Deventer SJ, Kuijper EJ, Speelman P. Clinical relevance of antibiotic-induced endotoxin release. *Antimicrob. Agents Chemother.* 1994;38(6):1211-1218.
- Rabinovitch A, Aviram I and Zaritsky A, Bacterial debris – an ecological mechanism for coexistence of bacteria and their viruses. *J Theor Biol* 224:377–383 (2003).
- Raji MA, Adekeye JO, Kwaga JKP, Bale JOO. *In vitro* and *in vivo* pathogenicity studies of *Escherichia coli* isolated from poultry in Nigeria. *Isr. J. Vet. Med.*[online]. 2003;58(1).
- Rohwer F, Edwards R. The phage proteomic tree: a genome-based taxonomy for phage. *J. Bacteriol.* 2002;184(16):4529-4535.
- Ronda C, Vázquez M, López R. Los bacteriófagos como herramienta para combatir infecciones en Acuicultura. *Revista Aquatic*. 2003;18:3-10.
- Saberfar E, Pourakbari B, Chabokdavan K, Dolatshahi FT. Antimicrobial susceptibility of *Escherichia coli* isolated from Iranian broiler chicken flocks, 2005-2006. *J. Appl. Poult. Res.* 2008;17(2):302-304
- Shao Y and Wang I, Bacteriophage adsorption rate and optimal lysis time. *Genetics* 180:471–482 (2008).
- Sklar IB, Joerger RD. Attempts to utilize bacteriophage to combat *Salmonella enterica* serovar Enteritidis infection in chickens. *J. Food Safety.* 2001;21(1):15- 29
- Smith HW, Huggins MB, Shaw KM. Factors influencing the survival and multiplication of bacteriophages in calves and in their environment. *J. Gen. Microbiol.* 1987;133(5):1127-1135.
- Smith HW, Huggins MB, Shaw KM. The control of experimental *Escherichia coli* diarrhoea in calves by means of bacteriophages. *J. Gen. Microbiol* 1987;133(5):1111-1126.
- Smith HW, Huggins MB. Effectiveness of phages in treating experimental *Escherichia coli* diarrhoea in calves, piglets and lambs. *J. Gen. Microbiol.* 1983;129(8):2659-2675.

- Smith HW, Huggins MB. Successful treatment of experimental *Escherichia coli* infections in mice using phage: its general superiority over antibiotics. *J.Gen.Microbiol.* 1982;128(2):307-318.
- Todar K. Mechanisms of bacterial pathogenicity: endotoxins. In: *Todar's Online Textbook of Bacteriology*. Madison, WI: University of Wisconsin-Madison 2002.
- Vaara M. Antibiotic-supersusceptible mutants of *Escherichia coli* and *Salmonella Typhimurium*. *Antimicrob. Agents Chemother.* 1993;37(11):2252-2255.
- Van den Bogaard AE, London N, Driessen C, Stobberingh EE. Antibiotic resistance of faecal *Escherichia coli* in poultry, poultry farmers and poultry slaughterers. *J. Antimicrob. Chemother.* 2001;47(6):763-771.
- Vandekerchove, D., De Herdt, P., Laevens, H. & Pasmans, F. (2004). Colibacillosis in caged layer hens: characteristics of the disease and the aetiological agent. *Avian Pathology*, 33, 117_125.
- Wagner EK, Martinez JH. *Basic Virology*. 2nd ed: Blackwell Publishing; 2004.
- WHO. WHO global strategy for containment of antimicrobial resistance. 2001:96.
- Williams KL. Endotoxin structure, function and activity. In: Williams KL, ed. *Endotoxins, pyrogens, LAL testing, and depyrogenation*. Vol 3. 2nd ed. New York: Marcel Dekker, Inc.; 2001:27-38.
- Wommack KE, Colwell RR. Virioplankton: Viruses in aquatic ecosystems. *Microbiol. Mol. Biol. Rev.* 2000;64(1):69.
- Young R, Wang I, Roof W. Phages will out: strategies of host cell lysis *TrendsMicrobiol.* 2000;8(3):120-128.
- Zanella, A., Alborali, G.L., Bardotti, M., Candotti, P., Guadagnini, P.F., Martino, P.A. & Stonfer, M. (2000). Severe *Escherichia coli* O111 septicaemia and polyserositis in hens at the start of lay. *Avian Pathology*, 29, 311_317.